Hypoglycaemia events with iGlarLixi versus premix biphasic insulin aspart 30 ( BIAsp 30) in people with type 2 diabetes advancing from basal insulin: An analysis of the SoliMix trial
Diabetes Obesity and Metabolism2022Vol. 24(12), pp. 2391–2399
Citations Over Time
Rory J. McCrimmon, Philip Home, Alice Cheng, Francesco Giorgino, Vivian Fonseca, Elisabeth Souhami, Agustina Alvarez, Pascaline Picard, Julio Rosenstock
Abstract
These results show that the lower HbA1c levels and weight benefit seen with iGlarLixi versus premixed BIAsp 30 in people with type 2 diabetes advancing their basal insulin therapy in the SoliMix trial are also accompanied by a lower risk of hypoglycaemia at any time of day and across a broad range of HbA1c levels.
Related Papers
- → A Simple and Rational Twice Daily Insulin Regime<subtitle>DISTINCTION BETWEEN BASAL AND MEAL INSULIN REQUIREMENTS</subtitle>(1979)33 cited
- A Simple and Rational Twice Daily Insulin Regime(1979)
- Review of biphasic insulin aspart in the treatment of type 1 and 2 diabetes.(2007)
- → Combining Basal Insulin and GLP-1 Agonists Is Effective in Advanced Type 2 Diabetes(2014)
- → Clinical Experience with Biphasic Insulin Aspart 30 (NovoMix® 30)(2010)